James is the CEO and co-founder of Precision NanoSystems, Inc. (PNI), a commercial stage biotechnology company at the convergence of nanotechnology, genomics, and precision medicine. PNI empowers researchers to advance nanomedicines for the treatment and diagnosis of disease. James earned a B.A.Sc. in engineering physics from UBC and a Ph.D. in genetics from the Institute for Systems Biology in Seattle, WA. James worked at the Seattle based Venture Capital firm, the Accelerator Corporation concurrent with his Ph.D. and has extensive experience in the science and commercialization of microfluidics, nanotechnology, and systems biology. James has lead PNI since its inception and has grown the Company to be the leading technology provider for the development of nanomedicines. James is a Director of Life Science British Columbia and an active participant of the bio-entrepreneurial community.
Clinical and Research Tools Showcase: Precision NanoSystems
Precision NanoSystems is uniquely positioned to offer the flexibility needed to move products from the clinical development stages through to commercial scale in a nimble and agile manner, accelerating the research and drug development process.
Enabling the Development of Nanomedicines for Precision Medicine
Nanomedicines permit access to previously undruggable pathways, overcome challenges of drug delivery, and enable exciting new precision therapeutic modalities like genetic medicines. In this talk, I will discuss the development of nanomedicines for precision medicines, and how they are ushering in the digitization of therapeutics.